Jeff Knudson
Analyst · Bank of America. Please go ahead
Thank you, Cary, and good afternoon everyone. Fourth quarter revenue of $1.126 billion was 4% above the high end of our guidance range with all three segments contributing to the outperformance. Consolidated revenue was down 17% year-over-year and 1% sequentially, excluding labor disruption revenue, consolidated revenue was in line with the prior quarter. Gross margin for the quarter was 33.3%, 140 basis points higher than prior year and down 50 basis points sequentially. Year-over-year, the margin was hired due to a revenue mix shift toward higher margin businesses. Sequentially, the margin was lower due to the typical seasonal revenue mix shift towards staffing. Consolidated SG&A expenses were $219 million or 19.5% of revenue, compared with $239 million or 17.5% of revenue in the year ago quarter, and $215 million or 18.9% of revenue in the previous quarter. SG&A expenses were lower year-over-year primarily due to lower employee related expenses, given less revenue and more normal operating conditions. Higher allowances for credit losses and legal reserve expenses drove the increase in SG&A compared with the prior quarter. Adjusted SG&A. excluding certain non-recurring expenses and stock-based compensation expense was $202 million this quarter, or 17.9% of revenue compared with $212 million or 15.6% of revenue in the year ago quarter. The increase in adjusted SG&A margin came from less operating leverage on lower revenue. In the fourth quarter, Nurse and Allied revenue was $825 million, 24% lower than prior year and slightly down sequentially. Average bill rate was lower by 2% quarter-over-quarter and average hours down 1%, offsetting 3% higher volume. Our travel nurse revenue was down 24% versus prior year and flat sequentially. Allied revenue was $195 million growing 6% from the prior year and 3% above prior quarter. Nurse and Allied gross margin of 26.6% was 40 basis points lower than prior year and prior quarter. The year-over-year change was caused by less labor disruption revenue, lower average hours and higher insurance expenses partially offset by improvement in the bill pay spread. Sequentially, the margin decreased stem primarily from the favorable workers compensation adjustments that occurred in Q3, segment operating margin of 12.7% was 370 basis points lower than prior year and 120 basis points lower than prior quarter, reflecting the higher allowances for credit losses. Physician and Leadership Solutions revenue in the fourth quarter was $168 million, 2% higher year-over-year and down 4% sequentially. Locum tenens revenue was $103 million, 4% higher than prior year or growing by 13%, excluding pandemic related revenue. Interim leadership revenue increased 4% from prior year and was down 5% from prior quarter. Search revenue declined 10% from prior year and was down 13% sequentially. Gross margin for this segment was 35%, 100 basis points higher than prior quarter and down 10 basis points year over year. The sequential margin increase was primarily due to higher gross margin for locum tenens partially offset by mix. Segment operating margin was 16.7%, up 510 basis points from last year and up 310 basis points sequentially. The higher profit margin came primarily from a lower allowance for credit losses and a favorable actuarial adjustment. Technology and Workforce Solutions revenue was $133 million in the fourth quarter, growing 14% year-over-year and down 1% sequentially. Language Services stood out with revenue of $58 million, which grew 23% year-over-year, and 5% quarter-over-quarter, BMS revenue of $55 million grew 5% year-over-year and was down 9% from prior quarter as we had expected. Segment gross margin was 73.3%, up 130 basis points over prior year and down 230 basis points sequentially. The year-over-year and sequential changes track revenue comparisons for the higher margin BMS business. Segment operating margin of 50.2% was up 280 basis points year-over-year and down 250 basis points sequentially. Consolidated fourth quarter adjusted EBITDA of $175 million was lower by 22% year-over-year and down 4% from the prior quarter. Adjusted EBITDA margin of 15.5% was 80 basis points lower year-over-year and down 50 basis points sequentially. We reported net income of $82 million and diluted earnings per share of $1.88 in the quarter. Adjusted earnings per share was $2.48 compared with $2.95 in the year ago quarter. Day sales outstanding came in better than expected at 55 days, four days less than the prior quarter and two days higher than prior year. Operating cash flow for the quarter was $115 million and capital expenditures were $25 million. As of December 31st, we had cash equivalents of $65 million, long-term debt of $850 million and a net leverage ratio of one time to one Recapping financial highlights for the full year 2022, we reported revenue of $5.2 4 billion, a 32% year-over-year increase and net income of $444 million, which grew by 36% compared with 2021. Adjusted EBITDA was $847 million, up 33% from prior year. Full year adjusted EBITDA margin of 16.1% was 20 basis points higher year-over-year. GAAP EPS was $9.90, up 45% year-over-year, adjusted EPS was $11.90 higher than prior year by 48%. EPS benefited from our repurchases of $577 million in stock during the year. Full year cash flow from operations was $654 million, which included a $24 million payment of deferred payroll taxes from the Cares Act, adjusting for the Cares Act repayment. nearly 80% of our adjusted EBITDA was converted into cash flow from operations. Capital expenditures totaled 76 million. Since the end of 2022, two events have bolstered our capital strategy, we obtained an expansion of our revolving line of credit adding $350 million of borrowing capacity to total $750 million with its tenor extended to 2028. The interest rate for the expanded facility is in line with previous terms. In addition, the Board of Directors expanded our share repurchase authorization by $500 million. Since our last earnings call, we bought back 2.4 million shares of stock for $275 million. The latest authorization gives us a total of $551 million in potential buybacks. Now looking at first quarter 2023 guidance. We project consolidated revenue to be in a range of $1.1 billion to $1.13 billion, down 27% to 29% over prior year. Gross margin is projected to be 32.6% to 33.1%. Reported SG&A expenses are projected to be 18.3% to 18.8% of revenue. Operating margin is expected to be 11% to 11.7%, and adjusted EBITDA margin is expected to be 15.4% to 15.9%. Average diluted shares outstanding are projected to be $42 million, reflecting our recent share repurchase activity. Other first quarter guidance details can be found in today's earnings release. Last quarter, we talked about 2023 returning to a normal seasonal pattern. Our fourth quarter results and first quarter outlook came in stronger than we had expected, with higher bill rates being a key driver. After the Q1 strength current business trends suggest a decline in Nurse and Allied revenue for Q2 that is greater than normal seasonality. While demand is still above pre pandemic levels, we have seen some clients pursue near term cost savings and reduce utilization of contingent staff. Labor market conditions remain very tight with high vacancies and attrition. And we believe staffing demand will go back up over the summer in line with normal seasonality. And now, I'd like to hand the call back to Cary.